Article
WVE-004 Trial in Patients With C9orf72 Mutations Gains Funding
Rating:
0.0
Views:
29
Likes:
1
Library:
1
Wave Life Sciences has gained additional financial support for an ongoing "basket" Phase 1b/2a clinical trial evaluating its experimental therapy, WVE-004, in people with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) caused by mutations in the C9orf72 gene. So-called...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value